We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 03, 2023

Carfilzomib Induction, Consolidation, and Maintenance ± ASCT in Patients With Newly Diagnosed Multiple Myeloma According to Cytogenetic Risk Status

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial
Lancet Oncol 2022 Dec 14;[EPub Ahead of Print], R Mina, P Musto, D Rota-Scalabrini, L Paris, B Gamberi, A Palmas, S Aquino, P de Fabritiis, N Giuliani, L De Rosa, A Gozzetti, C Cellini, L Bertamini, A Capra, D Oddolo, ID Vincelli, S Ronconi, V Pavone, N Pescosta, M Cea, F Fioritoni, S Ballanti, M Grasso, E Zamagni, A Belotti, M Boccadoro, F Gay

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading